<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>13</Volume>
				<Issue>1</Issue>
				<PubDate PubStatus="epublish">
					<Year>2012</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Expression of β-tubulin Ⅲ and Survivin in Advance Stage Breast Cancer Correlates with Chemotheraputic Effects of Docetaxel</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>361</FirstPage>
			<LastPage>365</LastPage>
			<ELocationID EIdType="pii">26153</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>Aims: To investigate the relationship between the expression of β-tubulinⅢ and survivin in advanced breastcancers and chemotherapeutic effects of docetaxel. &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: Clinical pathological data of 74 patients withadvanced breast cancer were retrospectively analyzed after docetaxel chemotherapy. Expression of β-tubulinⅢand survivin was assessed by immunohistochemistry and analyzed with reference to therapeutical and adverseeffects of docetaxel. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: The positive expression rate of β-tubulinⅢ was 38.1% (32/84), while that of survivinwas 76.2% (64/84). The effective rate (complete response + partial response) was 52.4%. That for patients withthe positive expression of β-tubulinⅢ or/and survivin was significantly lower than for those with negativeexpression (P&lt;0.05). There were significant differences in the non-progression of median diseases, 1-year and2-year survival rates of between the patients with positive and negative expression (P&lt;0.05). The main side effectswere myelosuppression, alimentary canal response and alopecie, no differences being observed between groups.&lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: The combined detection of β-tubulinⅢ and survivin is a predictive index for chemotherapy effectsof docetaxel in metastatic breast cancer.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">breast cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Docetaxel</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">β-tubulinⅢ</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Survivin</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Chemotherapy</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_26153_c0d7414f8560a1c0459a53db0ef6e822.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
